Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.
about
Clinical trials in severe sepsis with drotrecogin alfa (activated)Human recombinant activated protein C for severe sepsisHuman recombinant protein C for severe sepsis and septic shock in adult and paediatric patientsHuman recombinant activated protein C for severe sepsisHuman recombinant activated protein C for severe sepsisSurviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008Practical aspects of treatment with drotrecogin alfa (activated)Scientific and clinical challenges in sepsis.Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated).Recently published papers: therapies failed, disputed, and beneficent.The safety profile of drotrecogin alfa (activated).Increased bleeding risk associated with the use of recombinant human activated protein C in patients with advanced liver diseaseDrotrecogin alfa (activated): real-life use and outcomes for the UKEvaluation of recombinant activated protein C for severe sepsis at a tertiary academic medical center.Drotrecogin alpha (activated): the treatment for severe sepsis?Update in critical care 2007.Dissociation of activated protein C functions by elimination of protein S cofactor enhancement.Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort.The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomesGrowing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.Protective mechanisms of activated protein C in severe inflammatory disorders.Evaluation and management of shock States: hypovolemic, distributive, and cardiogenic shock.Protein C and acute inflammation: a clinical and biological perspective.Neuropeptide modulators of high mobility group box 1 secretion as potential therapeutic agents for severe sepsis.An update on activated protein C (xigris) in the management of sepsis.Recombinant activated protein C usage in Scotland: a comparison with published guidelines and a survey of attitudes.Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis.Canadian survey of critical care pharmacists' views and involvement in clinical research.
P2860
Q21195024-D9975235-7FB2-4180-84E8-AC70FBD05338Q24201123-9A8081F5-E2BE-4349-B47A-F07148AEE86CQ24202128-CC5E3C7C-0995-4C45-98D2-5A6985EF37FBQ24235181-5311DFCE-9A4E-4802-868E-123FE880074BQ24242859-26EF2449-FBBB-4449-ADEF-8021D8998038Q24644984-16E5DD5D-C27F-4287-B74F-C088873E0C77Q33378616-A4BBFFA5-A5C0-41B7-8389-181035B6BDA7Q34994107-E0C797C2-2DAA-4D06-AD1F-D565F2FEDDC2Q36112774-2EBF5A2E-282F-42B8-93FA-D1B3E33707A1Q36392485-0828C019-B87B-4470-9835-C553AD57BFE1Q36438845-6E890EBE-DC60-476A-A26A-81A1F3D9C543Q36642123-98A6B7E7-080E-4D45-987D-DC1CDD797C44Q36749140-AF6D318A-3CE9-4ABD-A196-4A8F4B358A73Q36919457-D5AC7AFF-850C-4C1E-80DC-9085D77321EFQ36981698-19EB2351-0DCB-47F3-B715-8FED1ACFB07DQ37129287-03175FE3-EF99-4DC1-BC54-168ACA264E7FQ37142684-7CDBBF29-DD36-418E-9BF6-2C9261A15B7FQ37279814-7C9ED608-B816-42C2-A442-A6CCB6C964CCQ37279933-9253B2AD-8709-48BC-B489-0EACE284661FQ37354434-E6D2EC71-60B2-4352-8756-7781BB881C6BQ37494702-0219D9EE-2024-45CD-B9EB-D17F98C84082Q37867315-5E2EF54E-D18D-42E3-8863-24F5E904ACA3Q38126264-6DE2DB1C-F5C1-4782-86BA-F058A26E3B7EQ41920965-460FE0CD-5E9F-4BF8-BBE3-4A0F3141F268Q42067556-2D0B9A0C-086C-42D1-A6D0-3BA448EF77ADQ48221454-A2DC3E9C-D0C0-473A-9B37-AD12DFE84C29Q49505268-6A8EDB9C-16C3-4831-9E88-D0579FB82817Q50916027-24AB31CE-780B-4B9E-9072-92F38EA47D35
P2860
Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Evaluating the use of Drotreco ...... lticenter observational study.
@en
type
label
Evaluating the use of Drotreco ...... lticenter observational study.
@en
prefLabel
Evaluating the use of Drotreco ...... lticenter observational study.
@en
P2093
P1476
Evaluating the use of Drotreco ...... ulticenter observational study
@en
P2093
Clarence Chant
David Williamson
Marc M Perreault
Salmaan Kanji
P2888
P304
P356
10.1007/S00134-007-0555-9
P50
P577
2007-02-15T00:00:00Z